Formulation and Drug Delivery, Controlled Release

AstraZeneca Gets Positive EMA Opinion on Respiratory Biologic

November 10, 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.

Accelerating Genetic Medicine R&D Using Microfluidics

September 15, 2017

This review examines how microfluidics has been used in the formulation, preclinical, and clinical development of gene-delivery nanoparticles.

Multiparticulate technologies hot for controlled release

October 01, 2016

Multiparticulates are increasingly used due to their flexibility in providing controlled-release, fixed-dose combinations, ease of taste-masking, and suitability for pediatric applications

Knowledge-Sharing and Networking at the CPhI Pre-Connect Congress

August 28, 2015

The Pre-Connect Congress will explore pharma industry trends, such as mergers and acquisitions, the biologics market outlook, and innovation in drug delivery among others.

Drug Delivery Systems for Biopharmaceuticals

August 01, 2015

Industry experts spoke to BioPharm International about the key considerations in the development of a drug-delivery device for a biologic drug, the importance of human factors engineering, the advantages of prefilled syringes, and the challenges in the manufacture of these devices.

Discovery Pipeline: Nanoparticles for Targeted Delivery

October 01, 2012

Recently published research demonstrates how nanoparticles can be used to overcome hurdles in localized drug delivery.

Discovery Pipeline: Topical Delivery of siRNA

August 01, 2012

A team from Northwestern University has demonstrated the feasibility of topical delivery of small interfering RNA (siRNA).

25 Years of Nanoparticles: A Look Forward

June 01, 2012

Panayiotis P. Constantinides of Biopharmaceutical & Drug Delivery Consulting on growth of nanoparticle delivery systems.

Advances in Single-Shot Vaccine Development

January 02, 2009

The disadvantages of the traditional vaccine regime (prime plus boost) have spurred the development of single-shot vaccines. This article describes the development and manufacture of a prototype single-shot vaccine that uses microspheres made from cross-linked modified dextran polymers for controlled release of the antigen.